Toronto Innovation Acceleration Partners – TIAP – specializes in venture building of
early-stage health science technologies emerging from our members.
TIAP was formerly MaRS Innovation
Our Members
TIAP’s portfolio draws from three universities, nine teaching hospitals and two research institutes. Learn more about our members.Learn More›
Work With Us
Through our member-exclusive funding programs and services, TIAP works with founders to bring their health science technologies to market faster.Learn More›
Recent News

Allogene Therapeutics enters collaboration with Notch Therapeutics
Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma
Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on …

Notch Therapeutics, a new company in the field of gene-modified T cell therapy
Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) — Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited …

Zealand Pharma Acquires Encycle Therapeutics
Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a …